- Home
- TDUP vs HRMY Comparison
TDUP vs HRMY Comparison
Compare TDUP & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDUP
- HRMY
- Stock Information
- Founded
- TDUP 2009
- HRMY 2017
- Country
- TDUP United States
- HRMY United States
- Employees
- TDUP N/A
- HRMY N/A
- Industry
- TDUP Catalog/Specialty Distribution
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- TDUP Consumer Discretionary
- HRMY Health Care
- Exchange
- TDUP Nasdaq
- HRMY Nasdaq
- Market Cap
- TDUP 1.3B
- HRMY 1.5B
- IPO Year
- TDUP 2021
- HRMY 2020
- Fundamental
- Price
- TDUP $8.51
- HRMY $29.32
- Analyst Decision
- TDUP Buy
- HRMY Strong Buy
- Analyst Count
- TDUP 3
- HRMY 10
- Target Price
- TDUP $12.50
- HRMY $50.80
- AVG Volume (30 Days)
- TDUP 1.5M
- HRMY 855.8K
- Earning Date
- TDUP 11-03-2025
- HRMY 11-04-2025
- Dividend Yield
- TDUP N/A
- HRMY N/A
- EPS Growth
- TDUP N/A
- HRMY 58.41
- EPS
- TDUP N/A
- HRMY 3.10
- Revenue
- TDUP $277,729,000.00
- HRMY $772,527,000.00
- Revenue This Year
- TDUP $18.15
- HRMY $20.10
- Revenue Next Year
- TDUP $9.93
- HRMY $16.50
- P/E Ratio
- TDUP N/A
- HRMY $9.47
- Revenue Growth
- TDUP 20.14
- HRMY 17.74
- 52 Week Low
- TDUP $0.50
- HRMY $25.52
- 52 Week High
- TDUP $12.28
- HRMY $40.93
- Technical
- Relative Strength Index (RSI)
- TDUP 39.58
- HRMY 53.83
- Support Level
- TDUP $8.49
- HRMY $25.52
- Resistance Level
- TDUP $9.45
- HRMY $30.96
- Average True Range (ATR)
- TDUP 0.42
- HRMY 0.90
- MACD
- TDUP -0.01
- HRMY 0.47
- Stochastic Oscillator
- TDUP 23.33
- HRMY 69.76
About TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.